Shots:

• The BTD is based on P-II CITYSCAPE study assessing Tiragolumab + Tecentriq vs Tecentriq + PBO as a 1L treatment of 135 patients in a ratio (1:1) with LA unresectable metastatic NSCLC whose tumors have high PD-L1 expression with no EGFR
• Result: improvement in ORR (37% vs 21%); reduction in the risk of disease worsening or death (42%); ORR (66% vs 24%); m-PFS (not reached vs 4.11 mos.); Grade 3 AEs (48% vs. 44%)
• Tiragolumab is a mAb designed to bind with TIGIT and works as an immune amplifier- by potentially enhancing the body’s immune response. The company is evaluating the tiragolumab across various settings in different tumor types- including lung- esophageal and cervical cancers

 ­ Ref: BusinessWire | Image: Genentech